Background The World Health Organization offers clear guidance on the development of national cancer control programmes based on a country's level of resources, yet the motivation to implement such programmes may be driven by factors other than resources.
Introduction
Liver cancer is the second leading cause of cancer death and sixth most common cancer worldwide, with the majority of known cases occurring in developing countries (Ferlay et al. 2013) . Clinical features of hepatocellular carcinoma (HCC), the main subtype of liver cancer, make it challenging to manage and contribute to a relatively poor prognosis compared with other cancers (Kim and Han 2012) . Late diagnosis is common, contributing to the high mortality rates for patients diagnosed with this disease (Dohmen et al. 2000; Chan et al. 2008; Stravitz et al. 2008; Santi et al. 2010) . Liver cancer has a complex aetiology, most often occurring as a result of hepatitis B (HBV) or hepatitis C (HCV) viruses (Perz et al. 2006) , but also following non-alcoholic fatty liver disease, cirrhosis and hemochromatosis (Lodato et al. 2006) . These conditions in turn have a wide range of risk factors including alcohol consumption, smoking, diabetes, obesity and aflatoxin exposure, sharing contaminated needles, injection drug use, sexual intercourse and transmission of HBV from mother to infant or among young siblings (Chuang et al. 2009; El-Serag 2012) .
At least 17 clinical guidelines have been developed worldwide for aspects of the diagnosis and management of liver cancer (Schmidt et al. 2011; Song et al. 2012a) . Most guidelines contain diagnostic algorithms, recommendations for diagnostic testing modalities (i.e. imaging, serological and/or histological), and treatment recommendations (including liver resection, liver transplant and drug treatments) (Song et al. 2012a) . One example is the Barcelona Clinic Liver Cancer staging and treatment strategy, in which tumours are classified and patients matched to treatments ranging from curative to symptomatic based on the characteristics of the tumour, comorbid diseases and other indicators of liver function (Forner et al. 2010) . In addition to recommendations for diagnosis and treatment, some guidelines contain recommendations for epidemiology, prevention, surveillance (including methods, frequency and target populations) and follow-up (Song et al. 2012a) . For example, in addition to diagnosis and treatment recommendations, the American Association for the Study of Liver Disease practice guidelines recommend screening patients at high risk of HCC (e.g. based on hepatitis, cirrhosis, age, race and gender) every 6 months using ultrasonography (Bruix and Sherman 2010) . Despite concerns about their quality (Schmidt et al. 2011; Song et al. 2012b ) and uptake (Sharma et al. 2011) , such guidelines have the potential to improve outcomes if fully implemented (Song et al. 2012a) .
Although the existence of clinical guidelines is promising, public-health interventions also could reduce the incidence of liver cancer. For example, the incidence of HBV, one of the leading causes of liver cancer, has decreased significantly in many, but not in all countries, because of the introduction of HBV vaccination programmes (Chongsrisawat et al. 2006; Ni and Chen 2010; Zhang et al. 2010; Gwack et al. 2011) . Primary prevention programmes aimed at preventing and limiting the impact of risk factors for liver cancer, including HCV, alcohol, obesity and aflatoxin, could also be beneficial (Cabibbo et al. 2012) . These could include needle exchange programmes, public policies to reduce the availability or increase the cost of alcohol, programmes to increase physical activity and reduce caloric intake, interventions to remove aflatoxin from the food chain and social-marketing campaigns. More targeted interventions could involve identifying high-risk groups such as injecting-drug users, heavy drinkers, people with obesity and migrants from hepatitis endemic areas, and providing counselling, screening, treatment and catch-up vaccinations for existing liver disease that could progress to liver cancer.
In terms of secondary prevention, a promising approach is to focus on early identification and treatment of liver-cancer cases (Della Corte and Colombo 2012). For example, the Japanese clinical guidelines and practice manual include consensus statements recommending that patients with HBV and HCV should be treated with antiviral or anti-inflammation therapy and be provided guidance on pathology, diagnosis and treatment based on disease pathology and progression and, moreover, that high-risk and super-high-risk patients should be identified based on existing liver disease severity and entered into HCC surveillance programmes in which they are tested with ultrasound and tumour markers at intervals determined by their risk level (Kudo et al. 2011) . Early identification strategies, as advocated by the Japanese, have been credited with improving prognoses (Kokudo and Makuuchi 2009; Kudo et al. 2011) . Similar outcomes have been found in other screening programmes aimed at early detection (Chen et al. 2002; Qian et al. 2010; Witjes et al. 2012) . There is also considerable optimism about several diagnostic and screening technologies that are at various stages of research and development (Carr 2012) .
Despite the many policy options that could have a positive impact, liver cancer is often neglected in general cancer control plans (Momin and Richardson 2011) , and few countries have implemented comprehensive plans for the control of liver cancer along the lines of what has been advocated for cervical [World Health organization (WHO 2006) ] and breast cancer control (Breast Health Global Initiative 2008) . Given the diverse and synergistic causes of liver cancer, the most promising approach would incorporate strategies to prevent liver cancer of all aetiologies alongside effective targeted screening and early intervention (Cabibbo et al. 2012) .
The WHO provides guidance for the formation and implementation of comprehensive national cancer programmes (WHO 2002 ) that could also be applied to a comprehensive liver cancer control plan. It recommends that all programmes incorporate four components of cancer control (prevention, early detection that includes screening and early diagnosis, treatment and palliative care), and are designed according to a common set of principles (goal orientation, focused on the needs of the people, systematic decision making process, systemic and comprehensive approach, leadership, partnership and continual improvement, innovation and creativity) (WHO 2002 (WHO , 2007 . Although the WHO envisages a similar process for all countries, it recommends different levels of comprehensiveness depending on countries' resource levels, with low-resource countries advised to focus on low-cost palliative care, low-midresource countries advised to focus on priorities in a demonstration area, and high-resource countries advised to seek full implementation of evidence-based strategies in a national cancer control framework (WHO 2002) . The WHO envisages a step-wise approach through planning and implementation, with planning steps focusing on deciding on the core package of interventions that will be implemented first, based on priorities and circumstances, implementation capacity, acceptability of interventions and the extent of support from political and nongovernmental stakeholders (WHO 2007) . Stakeholder involvement is thus an important, yet often neglected, component of comprehensive cancer control plans (WHO 2002; Rochester et al. 2011) . Stakeholders can have significant advocacy power in facilitating or blocking both policy formation and implementation, so it is important to understand their perspectives and motivation (Walt 1994) .
Significant needs for improving liver cancer control have been identified, yet there is evidence of heterogeneity in liver cancer control competence across countries (Bridges et al. 2011c (Bridges et al. , 2012b . The best performing countries are in Asia, where there is a known burden of disease and orchestrated policy responses (Amarapurkar et al. 2009; Poon et al. 2009; Farrell et al. 2010) . The worst performing countries are in Africa where hepatitis and cancer are often neglected diseases (Jemal et al. 2012; Morhason-Bello et al. 2013) .
The objective of this study was to compare stakeholder motivation to implement a national liver cancer control plan and document why motivation may differ across countries with differing levels of need and resources. Although stakeholder motivation is inherently important in healthcare, there is a paucity of research on comparing, or even measuring, stakeholder motivation for implementing healthcare programmes found in the literature.
Substantively, the study of stakeholder motivation for implementing a national liver cancer control plan is important as it contributes to the readiness of a country to adopt and accept the changes necessary to implement such a programme. The comparative approach enabled cross-country comparisons in the absence of a natural benchmark against which to assess motivation. Furthermore, the comparison of the motivation of a variety of countries with different levels of need and resources allows the exploration of what should be the potential drivers of change.
In terms of these predictors of motivation, we hypothesized that countries with more resources would have greater motivation. Comprehensive cancer control is usually addressed through a plan that pertains to multiple cancers, but the relative importance of liver cancer within the cancer field may vary across countries. Following this assumption, we also hypothesized that countries with a higher relative burden of liver cancer would have greater motivation to implement comprehensive liver cancer control.
Methods

Expectancy theory
To guide the development and interpretation of our work on stakeholder motivation, we have used expectancy theory (Georgopoulos et al. 1957; Vroom 1964) . Expectancy theory seeks to predict effort or actions based on motivation and has been applied mostly in industrial psychology studies predicting job performance, training outcomes and organizational change (Van Eerde and Thierry 1996; Lord et al. 2003; Lin et al. 2005; Gegenfurtner et al. 2009; Latham 2011 ) and other types of behaviour change (Eran and Jacobson 1976; Burkes 1991; Burton et al. 1992; Lee 2007; Johnson 2010) . Expectancy theory (Vroom 1964) posits that motivation for a given action can be measured using three factors:
(1) Expectancy-the perception of the stakeholder that exerting personal effort will achieve the desired action; (2) Instrumentality-the perception of the stakeholder that achieving the desired action will achieve the specified outcomes and (3) Valence-the value that the stakeholder placed on these specified outcomes.
Survey development
This study was completed as part of a larger study on stakeholders' perspectives about the needs and strategies for comprehensive liver cancer control. Both qualitative and quantitative methods were used to engage stakeholders in this project. First, the development of a study protocol was guided by an international advisory board, consisting of 23 liver-center experts from the study countries. Next, qualitative research, consisting of open-ended interviews with stakeholders from 11 countries (see Bridges et al. 2011a, b) , was conducted to inform the development of a survey instrument and protocol. This quantitative survey instrument was fielded in 13 countries to collect information on needs, priorities and motivation for implementing comprehensive liver cancer control. The countries represented in the study were Australia, China, France, Germany, Italy, Japan, (South) Korea, Nigeria, Taiwan, Thailand, Turkey, Spain and USA, which were somewhat opportunistically selected to provide geographic and socioeconomic diversity. At the time of the study, none of these countries had adopted a comprehensive liver cancer control plan. This article focuses on the sections of the survey that elicited information about respondents' roles and motivation for implementing comprehensive liver cancer control.
Respondents
Given the paucity of implemented national liver control plans and the complexity of the disease, it is somewhat difficult to define which stakeholders would be most relevant. Consistent with our previous research, and given that there are relatively few potential respondents in many of the countries, we purposively selected relevant stakeholders working in policy, clinical management or patient advocacy roles. Under the guidance of our research council, a combination of purposive and quota sampling was used to recruit similar types of respondents from each country.
Respondents were identified through a two-stage procedure. Initial selection was based on peer-reviewed publications, presentations at major liver disease conferences, leadership roles in national societies/centres, government agencies or recommendations from HCC-related research and other advisory groups. Email addresses were obtained from the same sources (e.g. email addresses listed for corresponding authors of peer-reviewed publications), or through searches of organizational websites with which potential respondents were affiliated. In the second stage of selection, respondents were included if they were oncologists, surgeons, radiologists, other HCC and hepatobiliary specialists, hepatologists, pathologists and other specialists who may be involved in HCC prevention, diagnosis, treatment and care, or leaders of major medical institutions (including cancer and other liver disease centres). Respondents were excluded if they were not board certified, had been certified for <1 year, had practised medicine for <3 years or had lived or practised in that jurisdiction for <3 years. Inclusion and exclusion criteria, which are described elsewhere (Bridges et al. 2012a) , were designed to ensure respondents had sufficient experience with liver cancer policy and practice in their country to enable them to answer the survey questions in a meaningful manner.
Potential respondents were sent emails requesting their participation in both English and the local language if appropriate. They received reminders by phone or email up to four times before being coded as 'non-response'. Interviewers assisted respondents to complete the survey in person (predominantly at their home institution) or by telephone. On the advice of the expert council, the survey asked respondents to self-identify according to their professional roles and interests. They identified their main area of involvement in liver cancer as being hepatitis, HCC, metastatic liver cancer or transplantation, and their involvement in liver cancer control as being at the local/municipality, regional/provincial, national or international level. Interviews were held between October 2010 and August 2012.
The study was reviewed by the Johns Hopkins Bloomberg School of Public Health, Institutional Review Board and deemed exempt from humans subjects review (#00000287).
Respondents were informed about the purpose of the study and potential risks and benefits of participation and they were informed that participation was voluntary and respondents received no reimbursement. A verbal confirmation of understanding and voluntary participation was sought from each respondent before commencing the survey.
A novel motivation scale
As there are no other empirical studies on the motivation of stakeholders for the implementation of cancer control programmes, we developed a novel scale grounded in expectancy theory. In developing the scale (see Figure 1) , we aimed to assess the stakeholders' level of motivation by applying the expectancy theory approach. Expectancy was measured by asking stakeholders to rate their agreement on a seven-point Likert scale with the statement 'Exerting your effort will help your country implement a comprehensive liver cancer control plan'. To assess instrumentality, stakeholders were asked to rate, again on seven-point Likert scales, their agreement that success in implementing a comprehensive liver cancer control plan would improve each of four specified outcomes of liver cancer control identified during our qualitative research (Bridges et al. 2011b) . The outcomes included public awareness, knowledge of HCC among primary care physicians, use of risk assessment among primary care physicians and referral of patients to expert care. Finally, valence was assessed by asking stakeholders to value, on a five-point Likert scale, the importance of achieving these specified outcomes for liver cancer control. Figure 1 shows a stylized version of the survey questions.
Given this was an experimental scale, we conducted only a simple pilot on 20 respondents (Bridges et al. 2011a ) to ascertain cognitive burden and the ability of stakeholders to complete the tasks. Field notes from the pilot indicated no problems or modifications to the survey instrument.
Statistical analysis
Survey data were coded for analysis and double checked for consistency. To test for the reliability of the instrumentality and valence subscales (each varying across the same four items), the Cronbach's alpha was used. The motivation for each stakeholder (M i ) was then calculated by combining the score for the single expectancy question (E i ) and instrumentality and valence subscales. Hence, this created a multiplicative motivation score as specified by equation (1).
Here, I ik and V ik were the instrumentality and valence ratings of respondent i for the four outcome measures k. Given this is measured on an arbitrary scale from 1 to 245, the motivation scores were rescaled to a 100-point scale to aid interpretation. Respondent characteristics obtained during the survey were coded using a series of dummy variables. Chi-squared tests were used to assess differences in respondent characteristics across countries. As seen in equation 2, ordinary least squares regression was used to regress the motivation for individual i in country j (M ij ), a vector of stakeholder characteristics (Si) and a set of country level fixed effects (' j ).
The stakeholder characteristics included their role (clinical, policy or advocacy), involvement in hepatitis and whether they were involved in liver cancer policy primarily at the local/municipality, regional/national or international jurisdictional levels. Wald tests were used to test for differences between coefficients.
Similarly, specified equations were used for the valence, instrumentality and expectancy subscales. The dependent variables for valence and instrumentality were the respondents' average valence (from 1 to 5) and instrumentality (from 1 to 7) ratings across the four outcomes. The dependent variable for the expectancy model was respondents' response to the expectancy question in the survey (from 1 to 7).
The coefficients for the set of country dummy variables were equivalent to the mean motivation scores, adjusted for differences across countries in respondent characteristics. Pearson correlation coefficients were calculated between these 13 adjusted mean scores and country-level variables measuring resources and relative burden of liver cancer. All analyses were conducted in Stata 11.2 (StataCorp LP, College Station, Texas).
Other data sources
In the absence of a more specific measure of the health sector resources needed for implementation of a liver cancer plan, resources were measured using gross domestic product (GDP) per capita in 2011 US dollars, adjusted for purchasing power parity (PPP, a measure that takes into account the different prices of goods and services across countries) (International Monetary Fund 2012) . The relative burden of liver cancer was estimated as the ratio of liver cancer deaths to all cancer deaths for each country in 2008, the most recent year for which data were available (Ferlay et al. 2010) .
Results
A total of 625 potential stakeholders were identified (see Figure 2 ). Of these, 15 did not meet inclusion criteria, 32 were not required, 69 declined to participate (most often citing time constraints), 27 stakeholders did not complete the interview and 222 did not respond (including both those who did not want to participate and those for which our contact information was wrong). In the absence of financial incentives, the response rate (45%) was relatively high, ranging from 22% in USA to 100% in Japan. Table 1 shows respondent characteristics of the respondents by country.
Countries differed in the proportion of respondents that were involved at the local (P ¼ 0.002) and international (P < 0.001) levels, relative to regional/national levels. A relatively high proportion of respondents from Nigeria and Thailand worked at the local level (30%), and over half of stakeholders sampled from Italy and the USA worked at the international level. Respondents also differed across countries in their main areas of involvement in liver cancer (P ¼ 0.001) with at least half of the respondents from Australia, Nigeria, Thailand and USA working mainly in hepatitis.
The last two columns of Table 1 show the GDP and liver cancer burden measures used for calculating the correlations with motivation. Resource levels ranged from $2582 for Nigeria to $48 328 in the USA. The relative burden of liver cancer also had a wide range, with liver cancer being responsible for between 2% (Australia and Turkey) and 27% (Thailand) of all deaths from cancer. The instrumentality and valence subscales were both found to be sufficiently reliable (Cronbach's ¼ 0.69 and 0.67, respectively) with average inter-item covariances of 0.45 and 0.25, respectively. Table 2 shows each country's unadjusted mean score (and standard error) for the valence, instrumentality and expectancy subscales and for motivation. Unadjusted mean motivation scores ranged from a low of 42.3 for Italian respondents to a high of 74.2 for Nigerian respondents. The table also shows the mean motivation scores adjusted for respondent characteristics. Adjustment changed the mean scores by up to 2.9 points (in Italy) but did not change the order of results. Replacing the country level dummy variables in the regression equation with a constant gave the overall adjusted mean of 57.2. The last two columns in Table 2 show the difference between the overall adjusted mean and each country's adjusted mean, and the P-value for this comparison, obtained from Wald tests. Adjusted mean motivation was significantly above average among respondents from Nigeria, Thailand and China (P < 0.001) and significantly below average among respondents from Italy (P < 0.001) and Germany (P ¼ 0.003).
As seen in Figure 3 , the country level estimates of motivation, holding constant the difference in the stakeholder mix of each country, were positively correlated with the relative burden of liver cancer ( ¼ 0.654; P ¼ 0.015) and negatively associated with their level of resources ( ¼ À0.642; P ¼ 0.018).
Discussion
Using a new measure of motivation to implement comprehensive liver cancer control plans, we found motivation was particularly high among stakeholders in Nigeria, Thailand and China. Motivation was particularly low among stakeholders working primarily at the local/municipality level and those from Italy and Germany. Motivation was higher among respondents from countries where liver cancer comprises a greater proportion of the burden of death from cancer, but lower among respondents from countries with more resources. In general, the same countries scored above or below average on the valence, instrumentality and expectancy components as for motivation overall, indicating that no subscale had a disproportionate impact on the results. The findings of high motivation to implement comprehensive liver cancer control in Nigeria, Thailand and China, and low motivation in Italy and Germany have implications for predicting which countries could have success in this area in the near future. Successful policy implementation (Walt 1994; Kingdon 1995; Brugha and Varvasovszky 2000; Sabatier 2007 ) requires motivated stakeholders as they play critical roles in formulating and implementing policies. Expectancy theory provides a way of quantifying stakeholder motivation in order to predict change, specifically in terms of stakeholder views of whether their efforts can make a difference, whether successful implementation will improve the outcomes of interest, and whether the outcomes of interest are important (Vroom 1964) . Decision makers in Nigeria, Thailand and China should actively seek involvement of liver cancer stakeholders to formulate and implement comprehensive liver cancer control plans while they are in a position to benefit from these key stakeholders' high levels of motivation. Taiwanese stakeholders also have a strong belief that exerting their efforts will help Taiwan to implement a comprehensive liver cancer control plan, suggesting decision makers should work with stakeholders to identify whether a different set of outcomes (e.g. the treatment of HCV) might be more important or likely to improve as a result of implementing a plan. Although motivation was generally high among all stakeholders, there was significant variation across countries. As such, decision makers in countries where stakeholders are less motivated to implement strategies may benefit from strategies to promote motivation if comprehensive liver cancer control is desired. Furthermore, it may be appropriate for countries with lower motivation to engage in cross country comparisons/dialogue to understand why they lack motivation and to identify strategies for improvement. The finding of lower motivation among stakeholders working at the local/municipality level relative to those working at the international level has two possible causal interpretations, or both may be a result of other factors (Luukkonen et al. 1992) . The most influential stakeholders may seek positions where they can work at the international level, or international work may lead to increased belief in their own ability to help implement policy. If the latter is true, it may be possible to increase motivation by encouraging more international collaboration. This may expose stakeholders to a broader policy community, with new ideas and examples of successes, which may facilitate collaboration. Similarly, the lower valence scores among those working at the local/municipality level, indicating they do not consider improvements in the four outcomes to be particularly important, suggests these stakeholders are less likely to facilitate implementation of comprehensive liver cancer control or that they may be more interested in a different set of outcomes. These findings suggest that decision makers planning to introduce comprehensive liver cancer control plans should ensure internationally active stakeholders are involved to promote implementation success.
The finding that higher motivation is correlated with a higher burden of liver cancer relative to other cancers indicates that motivation is not independent of the epidemiological (and hence perhaps political) status of liver cancer in a given country. Stakeholders from Italy and Japan had lower than average valence, which was consistent with the overall low motivation in Italy, but may reflect a belief that some of the outcomes considered in the valence question are already relatively well developed in Japan [e.g. risk assessment and referral (Bridges et al. 2011c) ], and therefore, additional improvements are relatively unimportant. Low instrumentality scores among stakeholders from Germany and Italy suggests they may believe improvements in these areas would not have a significant impact or that a comprehensive liver cancer control plan would be ineffective in achieving improvements in those areas, either because there is little room for improvement or because those areas are unlikely to be affected by a comprehensive plan. This would be consistent with the common approach of assessing needs for cancer control based on epidemiological patterns (Abed et al. 2000; Stevens 2004) . It also suggests possible benefits from targeted engagement about the barriers to realizing potential outcome improvements from comprehensive liver cancer control plans. The lower expectancy scores among respondents from Italy, Germany and Australia, indicating they believe that exerting their effort is relatively unlikely to help their country implement a comprehensive liver cancer control plan, could be due to a perception of low political awareness of the problem (Bridges et al. 2011c; Bridges et al. 2012b; Joy et al. 2013) or to a perception that they have little influence on decision makers. If this is the case, it could be beneficial to consider targeting interventions towards improving stakeholders' advocacy skills to increase their capacity to influence the implementation of comprehensive liver cancer control plans.
Aside from the fact that liver cancer is primarily a disease of developing countries (Ferlay et al. 2013) it is less clear why GDP per capita might be negatively correlated with motivation. It is unlikely that stakeholders from richer countries believe that liver cancer control is already sufficient in their countries, because results from this same survey found that stakeholders from richer countries considered their countries' performance on liver cancer control to be suboptimal (Bridges et al. 2011c (Bridges et al. , 2012b . Regardless of the reason, the finding has implications for international cancer control policy. The WHO recommends that countries with more resources implement more comprehensive cancer control plans than countries with fewer resources (WHO 2002) , but our findings suggest liver cancer stakeholders may be at odds with that view, and in fact that we might predict greater success in implementing comprehensive liver cancer control plans in lower resource countries, provided there are low-cost interventions available, based on their higher levels of stakeholder motivation. Although resource levels are obviously important in deciding what may be possible, a more responsive approach to prioritizing resources for cancer control would be to conduct comprehensive needs assessments that incorporate quantitative and qualitative analyses of stakeholder views, epidemiology, aetiology, political and systems factors, as well as financial resources.
A limitation of this study is that for the countries included in the survey GDP per capita and liver cancer mortality as a proportion of all cancer mortality were highly correlated. A measure that provided a better reflection of the resources available to implement a liver cancer plan might have mitigated this issue, but such a measure was not available. Measures of healthcare expenditure were considered no better for this purpose because they are confounded with existing policy choices as opposed to the system's potential to address the problem. Future research should attempt to separate the effects of these two variables by investigating motivation in higher resource countries with a higher burden of liver cancer and lower resource countries with a lower burden of liver cancer, and by considering other measures of resources. Furthermore, our comparison of motivation, albeit exploratory, with other indicators such as resources and need-which themselves may be poorly measured-is a limitation. This said, our approach is rather novel and highlights the need to consider stakeholder motivation in the formation of health care programmes.
A second limitation of the study is that the method could not provide a complete stakeholder analysis. Stakeholder analysis generally involves an assessment of the influence of stakeholders on policy decisions or implementation processes, often through considering actors' behaviour, intentions, networks, interests and influence or power, mostly not only through qualitative but also some quantitative methods . A quantitative stakeholder analysis cannot provide the same depth as a qualitative analysis, risks missing important issues and ignores the perspectives of actors outside the liver disease community who could have a significant influence on facilitating or blocking liver cancer policy. However, our method did permit robust comparisons of stakeholder motivation across countries.
A third limitation of the study regards the applicability and relevance of expectancy theory to the study of cancer control. Given that this is a novel application of expectancy theory, it is difficult to assess whether we have successfully completed this analysis, and as such, the utility of findings in practice. Furthermore, slight modifications to our motivation measure may have seen some different results. For example, it was possible that motivation subscale results could differ from overall motivation results. To test this we ran regression models identical to that specified earlier, but with scores on the valence, instrumentality and expectancy subscales as the dependent variable. As expected, subscale results were similar to those from the main approach, implying reliability in our measure. Given a lack of other benchmarks, however, it is difficult to assess the validity of our approach. Furthermore, this is a novel application that is likely to lead to future studies relating to motivation as it pertains to the implementation of health care programmes.
A fourth limitation regarding this study relates to the sampling strategy. Although we used a purposive quota sampling strategy to get equal number of stakeholders working in policy, patient advocacy or clinical roles from each country, there was variation within groups. Furthermore, we did not survey all possible stakeholders that may be relevant to the implementation of a national liver control plan. An overall response rate of 45% is reasonable given that this included non-response (e.g. we may have had the wrong contact information for the respondent), that we were using quota sampling (i.e. some respondents were not needed given that quota had been filled) and that no incentives were given to participate. Importantly, there was variation in the participation rate across the countries, which may have been related to motivation.
This study has provided a novel application of expectancy theory to stakeholder motivation in relation to policy implementation. Because the application is novel, however, there is no evidence of predictive validity in terms of predicting whether comprehensive liver cancer control plans will actually be implemented where stakeholders have higher levels of motivation. An important direction for future research will be to evaluate the extent to which these results do in fact predict changes in liver cancer policy. The fact that results were significant and the scale was reliable also demonstrates surveys of this nature could have much broader application in health policy. Given the importance of engaging stakeholders in cancer control, an obvious next step would be to replicate this survey for other types of cancers, especially where there is scope to improve cancer control strategies. Furthermore, more research is needed to examine this study question in other samples of stakeholders, using other sampling and data collection mechanisms. Such detail could be achieved if one focused on a single country and looked at regional or institutional variation in motivation.
Conclusion
Stakeholder involvement is an important, yet often neglected, component of comprehensive cancer control plans (WHO 2002; Rochester et al. 2011) . This current study demonstrates the value of a comparative quantitative consultation exercise with key stakeholders that decision makers could use as a starting point to develop comprehensive liver cancer control (CLCC) plans. In addition to providing technical input into policy development, stakeholders have a critical role throughout the policy process (Van Meter and Van Horn 1975; Walt 1994; Kingdon 1995; Sabatier 2007) ; suggesting further stakeholder analysis could be fruitful in the field of liver cancer policy. In this study, we found evidence of high motivation for implementing comprehensive liver cancer control plans among stakeholders in 13 diverse countries, and particularly high motivation in Nigeria, Thailand and China, countries that have relatively low GDP per capita and where the relative burden of liver cancer is high. Decision makers should take advantage of this high motivation by collaborating with stakeholders to increase the chance of successful implementation of liver cancer control plans. International collaboration is also likely to be beneficial because the insights of highly motivated stakeholders from other countries who work at the international level may facilitate the spread of best practices. Based on these findings, we hypothesize that high stakeholder motivation may lead to improvements in liver cancer control, particularly in countries suffering the greatest burden of disease from liver cancer.
